Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

12 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NYTQSVE6S3m2b4TvfIlkKEG|c3H5 Mn;INVAhdk1? NX;sVXl2PzJiaB?= NW\qSXJoTE2VTx?= MnW0VI91\W62aXH0[ZMh[2GvcITveIhm[2mwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 NY\oeW1POjR7MEC4O|M>
HT-29 MXjDfZRwfG:6aXOgRZN{[Xl? NXexV|B3OTBibl2= NXLwVWFbPzJiaB?= M4nh[WROW09? MoPKVI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7 NHvyO4MzPDlyMEi3Ny=>
HT-29 MXLDfZRwfG:6aXOgRZN{[Xl? NYfJXmtmOTBibl2= NGi0UVk4OiCq NWLkdWRYTE2VTx?= MYjQc5RmdnSrYYTld{A2NW[udX;yc5Vz[WOrbD3pcoR2[2WmIHP5eI91d3irY3n0fS=> MVOyOFkxODh5Mx?=
PC3 M{XJXmtqdmG|ZTDBd5NigQ>? NXfTc2xWOTByIH7N MUmxJIg> M1f2UGROW09? NESwV|BRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> Mnm2NlE6Pzh4OEO=
PC3 NFrISINMcW6jc3WgRZN{[Xl? MoTLNVAxKG6P NVj1dG1pOSCq NXnBXWl5TE2VTx?= Mmf1SI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? NHvWcokzOTl5OE[4Ny=>
PC3 NG\YOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDlXoxKOS53IN88US=> NHLaVncyKGh? M1jueGROW09? MWnJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KHerdHigTWM2OCCxZjC8NVAhdk1? MkG3NlE6Pzh4OEO=
HEK293 M4DH[GZ2dmO2aX;uJGF{e2G7 NUTKclNtOTByIH7N MnHvPEBp NHLVWmRFVVOR M37rNmlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= NGn4PFkzOTV|OUOwNS=>
BT-20 MnfVT4lv[XOnIFHzd4F6 MoD0NlAh|ryP MY\EUXNQ MWPEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? M4[5TVIyOzV|NUWx
U937 MmfZRY51cWKjY4TldolidCCDc4PhfS=> NH3z[3k2OCEQvF2= M1vwUlQ5KGh? NGSxTFdFVVOR MV;JcoR2[2W|IHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhVGWpaX;u[Yxt[SCybnX1cY9xcGmuYTDQbIlt[WSnbIDobYEuOSCMUkOyJIlvKFV7M{egZ4VtdHN? NGLlOXEzOTF2MkGwOi=>
U937 MoPNRY51cWKjY4TldolidCCDc4PhfS=> M4iyNVUxKM7:TR?= M2LjfFQ5KGh? M3TvOWROW09? NUfndVRGTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= Moi1NlEyPDJzME[=
U937 M4r2SGFvfGmkYXP0[ZJq[WxiQYPzZZk> NFvmSnY2OCEQvF2= NYXX[2VOPDhiaB?= M1jzTWROW09? NXfQeHpqTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCHc3Po[ZJq[2irYTDjc4xqKEiEMUCxJIlvKFV7M{egZ4VtdHN? NYHpSpZ5OjFzNEKxNFY>
MCF-7 M{LUdWF2fG:yaHHnfUBCe3OjeR?= NGDFbFA{OCCwTR?= NXvVVGJZPCCq MoX1SG1UVw>? NXLCdmdXUW6mdXPld{BifXSxcHjh[5k> NYXKfIs{OjByMkixN|Q>
U87MG MXfLbY5ie2ViQYPzZZk> NXzz[2dqOSEQvF2= MlXIOkBp NYjvVJZITE2VTx?= M2HveHBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w MoLlNVk5PDh2MES=
U87MG NFnQ[VBMcW6jc3WgRZN{[Xl? MVmxJO69VQ>? MX22JIg> MVfEUXNQ MmXuVI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= MU[xPVg1QDRyNB?=
U87MG NXfnR5BzU2mwYYPlJGF{e2G7 NXS3cYFNOSEQvF2= MmnxOkBp NV3zOFdLTE2VTx?= NFfqeFZFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= NVjvWm1GOTl6NEi0NFQ>
U87MG NVrMfYYxU2mwYYPlJGF{e2G7 MVuxJO69VQ>? NIPi[3E3KGh? MlzySG1UVw>? MmrzSI9meyCwb4SgbY5pcWKrdDDQMVRGSlBzKGSzO{81PilicHjvd5Bpd3K7bHH0bY9v MXixPVg1QDRyNB?=
COS7 cells expressing EGFP-HDQ74/rheb M{T1OGF2fG:yaHHnfUBCe3OjeR?= Mlr0NE4zKM7:TR?= NUT5[XNnOjRiaB?= M33Qb2ROW09? MX\JcoR2[2W|IHH1eI9xcGGpeR?= MYGxPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3 MnrsRZV1d3CqYXf5JGF{e2G7 M4[yOVAvOiEQvF2= MVeyOEBp NUDTZlRjTE2VTx?= Mmf5TY5lfWOnczDheZRweGijZ4m= Ml;ZNVg{QTF7NEm=
H4 Mn;wSpVv[3Srb36gRZN{[Xl? MWCwMlIh|ryP NIToVJozPCCq Mnq4SG1UVw>? NGe1enBKdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{ NIGzd3MyQDB{NEW4OC=>
HeLa NEKydFBHfW6ldHnvckBCe3OjeR?= NYLCcYh{OTByIH7N NV;rTHd4OzZiaB?= MkDsSG1UVw>? MUDJcoR2[2W|IF\SRkBMOjB7NWCsJHQzODl6TDygW|IyODGIIH31eIFvfC23YnnxeYl1cW6FIHnueIVz[WO2aX;u MVmxO|U3OzN6NR?=
HeLa M{TPPGZ2dmO2aX;uJGF{e2G7 NIfLRoMyODBibl2= MnvMN|YhcA>? NUDJSWxlTE2VTx?= M3vBeWlv\HWlZYOgSnJDKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? NVPrZ5pWOTd3NkOzPFU>
HeLa NXy4fJZwTnWwY4Tpc44hSXO|YYm= MXyxNFAhdk1? MWqzOkBp MmXLSG1UVw>? NXi5UXp4UW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v NFrWflQyPzV4M{O4OS=>
SYF Mlr0SpVv[3Srb36gRZN{[Xl? NH\H[GUyODBibl2= NXrhRZprOjRiaB?= NFzmNWJFVVOR MljyTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u MVOxO|U3OzN6NR?=
SYF MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7GUmoyODBibl2= MofXNlQhcA>? NEPWfnJFVVOR MYnJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiU2nGJINmdGy| M3PNblE4PTZ|M{i1
HEK293T NGX6dHVCdnSrdnnyZYwhSXO|YYm= MVmxJI5O NUTjTlF7PCCm M4DaR2ROW09? NXjadpc2UW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGK1JJdqfGhiRVO1NEBw\iByLkGgcm0> M1rGR|E4PDh3NUCx
HEK293T MVvBcpRqfmm{YXygRZN{[Xl? NI\5c|MyKG6P M4PwWFQh\A>? NIDZUm9FVVOR NH;icmtKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> MoflNVc1QDV3MEG=
PBMC NH\4[WtHfW6ldHnvckBCe3OjeR?= NIfUOlUyKG6P MoPzNVQh\A>? M3PhfWROW09? NV;hN41XWmWmdXPld{BES1J3IHTlcpNqfHl? NWnuN5hOOTd2OEW1NFE>
PBMC M1X2TmZ2dmO2aX;uJGF{e2G7 Mle0NUBvVQ>? NEn2Z|QyPCCm MXHEUXNQ MlnOSI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> NEfSOIgyPzR6NUWwNS=>
HEK293 cells MUDLbY5ie2ViQYPzZZk> MWi1NEBvVQ>? NH\tWHM1PSCvaX6= Ml72SG1UVw>? MoT6TY5pcWKrdIOgcXRQWiCtaX7hd4Uh[WO2aY\peJkhf2m2aDDJR|UxKG:oIECuNUBvVQ>? NW[wO2JbOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NXvRNXVJTnWwY4Tpc44hSXO|YYm= MYKxNFAhdk1? MVK0JIg> MnOxSG1UVw>? M2jxVWlv\HWlZYOgcJVkcW[ncnHz[UBxem:2ZXnuJJRz[W6|LYPwcIlkcW6pIHnuJGRzd3OxcHjpcIEhdWWuYX7v[4F{fGW{IGOyJINmdGy|IITyZY5{\mWldHXkJJdqfGhiTj3seYMh[W6mIFOtcJVk NWSwPGo{OTdzMkiyOlI>
Human mixed lymphocyte MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELLe3A2KG6P NI\ifoZFVVOR MVLJR|UxRTFwNjDuUU4> NXvabppPOTZzOEW4OlU>
Lewis rat lymph node cells NX20TWc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXrOUDPxE1? M{nyPGROW09? NGnNNnZKSzVyPUKuOkDPxE1? NY\TZW0yOTZzOEW4OlU>
cells from the thymus of normal BALB/c mice NYi0TZdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{CyWFExKG6P NWSwXpNVPzJiaB?= MUTEUXNQ NIXNOI9KdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7N NWXqS5JpOTByMkG5OFg>
MRK-nu-1 Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH4TWM2OD1yLki0OUBxVQ>? MUDTRW5ITVJ?
OCUB-M Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G3fGlEPTB;NT6yOEBxVQ>? MWnTRW5ITVJ?
SF539 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml71TWM2OD1zMT62JJBO Mo[zV2FPT0WU
ES4 M2PBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJzLkWgdG0> NEXCSGFUSU6JRWK=
RL95-2 MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm3V|BKSzVyPUGwO{BxVQ>? NVq3dmtbW0GQR1XS
LC-2-ad M4DhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrqRoU{UUN3ME20NlMheE1? MWnTRW5ITVJ?
Daudi Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTR|NDDwUS=> MUnTRW5ITVJ?
NTERA-S-cl-D1 NIDWdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HpdmlEPTB;NESzJJBO NWD0ZVJCW0GQR1XS
OS-RC-2 NIXnXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\4TWM2OD14NUKgdG0> NUmyZnNMW0GQR1XS
VA-ES-BJ Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL0SFczUUN3ME23NlMheE1? M4rzWnNCVkeHUh?=
GR-ST MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXNPZd4UUN3ME24OFYheE1? MYLTRW5ITVJ?
SW872 NEnSUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrjb|hKSzVyPUi0OkBxVQ>? M17Z[3NCVkeHUh?=
NOS-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nCNGlEPTB;OEexJJBO NVX4NodpW0GQR1XS
MC116 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGiyRYRKSzVyPUm4OUBxVQ>? M4\wTHNCVkeHUh?=
NCI-H1355 MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX6y[lg{UUN3ME2xMlAyKG6P MWHTRW5ITVJ?
RPMI-8226 MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTFwMUmgcm0> M1TmRnNCVkeHUh?=
TE-15 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLLeYpNUUN3ME2xMlM3KG6P MVLTRW5ITVJ?
Ramos-2G6-4C10 NGHHbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT2PG1EUUN3ME2xMlQ3KG6P MWjTRW5ITVJ?
KU812 MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHKz[lhKSzVyPUKuNFEhdk1? M3:3WXNCVkeHUh?=
EW-1 NYTicJkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJwMUegcm0> NG\xV3FUSU6JRWK=
KS-1 NXrvdZlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJwNEWgcm0> NVTncppbW0GQR1XS
SK-LMS-1 MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLxTWM2OD1{LkS5JI5O Ml[4V2FPT0WU
TGBC1TKB M3jCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP3TWM2OD1{Lk[5JI5O NUTneZVVW0GQR1XS
TE-6 MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjrOG0xUUN3ME2yMlc4KG6P MnKyV2FPT0WU
ETK-1 NEfWe3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUCxeldQUUN3ME2yMlgzKG6P NI\vTm5USU6JRWK=
BE-13 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfKd2Q{UUN3ME2yMlk6KG6P NWjQeYkxW0GQR1XS
A3-KAW M2\vNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXrTWM2OD1{Lkm5JI5O M1vRbnNCVkeHUh?=
TE-10 NF7NXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPRTWM2OD1|LkOgcm0> M1;QeXNCVkeHUh?=
DOHH-2 M{jZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PKV2lEPTB;Mz6zOUBvVQ>? NHXhfZdUSU6JRWK=
ES6 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHYRYRKSzVyPUOuOFMhdk1? NHLZc4lUSU6JRWK=
OPM-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvSUGNKSzVyPUSuNVUhdk1? NXfqfGRIW0GQR1XS
SH-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTRwM{Sgcm0> NGX1[ZRUSU6JRWK=
NB13 Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHv[pFkUUN3ME20MlM3KG6P NEPkTGtUSU6JRWK=
HUTU-80 M3i1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PSbmlEPTB;ND60NkBvVQ>? NUPKS2J1W0GQR1XS
CCRF-CEM NWDkdZJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvqTWM2OD12Lkm0JI5O MlO2V2FPT0WU
TGBC24TKB MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTVwNUGgcm0> NX\HdmMyW0GQR1XS
697 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHHTWM2OD14LkK4JI5O NHzDT5ZUSU6JRWK=
J-RT3-T3-5 M4\1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTZwNE[gcm0> NYXEUG1[W0GQR1XS
KALS-1 NHrXdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TxUmlEPTB;Nj61OkBvVQ>? NFLxbmpUSU6JRWK=
no-10 NGf5RnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTdwMkmgcm0> NUPRdIhNW0GQR1XS
SK-NEP-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRThwN{mgcm0> MVzTRW5ITVJ?
L-540 NXvX[odFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFyLkSyJI5O MWjTRW5ITVJ?
JiyoyeP-2003 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFyLkm0JI5O MXTTRW5ITVJ?
HH NIDyS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHRTWM2OD1zMT6zPUBvVQ>? NWnieGw5W0GQR1XS
SR MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j1eWlEPTB;MUGuOFUhdk1? NGTXNmVUSU6JRWK=
QIMR-WIL NEft[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFzLki1JI5O NH7UWJZUSU6JRWK=
A4-Fuk MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF|LkGyJI5O MmfDV2FPT0WU
CESS NH\XNIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nCd2lEPTB;MUOuNVMhdk1? MWDTRW5ITVJ?
KE-37 MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3QTWM2OD1zNj6wO{BvVQ>? NFHtN|dUSU6JRWK=
SK-UT-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S4dGlEPTB;MU[uPFEhdk1? MlGzV2FPT0WU
SIG-M5 Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTF5LkK1JI5O M{jGXnNCVkeHUh?=
HT M3HBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF5Lk[gcm0> NVLSZ|FJW0GQR1XS
DEL NEHVb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fMS2lEPTB;MUeuPVkhdk1? NEfGSoRUSU6JRWK=
SK-PN-DW M1fpe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGwd|ZKSzVyPUKwMlI{KG6P NU\ORWZRW0GQR1XS
RPMI-8402 NXnVblZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJzLke3JI5O MWnTRW5ITVJ?
RPMI-6666 MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYCyOoVnUUN3ME2yOE41OiCwTR?= NXnKS2ZDW0GQR1XS
NCI-H720 NWLmOlJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJ3LkSxJI5O NFfVc|FUSU6JRWK=
EW-16 NGjF[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnvUWRKSzVyPUK2Mlg4KG6P NEn3e2FUSU6JRWK=
BL-70 NW\BfGFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4WxcmlEPTB;MkiuN|ghdk1? NXL4SGtxW0GQR1XS
SF126 M1zLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;4NFlKSzVyPUOwMlM5KG6P M2nKVnNCVkeHUh?=
BC-1 NHjLTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTNzLkK2JI5O M3q2VXNCVkeHUh?=
MHH-PREB-1 M{WzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjSNm9JUUN3ME2zNk41PCCwTR?= Ml3RV2FPT0WU
A101D M2rVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTN{Lk[yJI5O NEPySopUSU6JRWK=
NMC-G1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTN|Lk[3JI5O NUm0foN5W0GQR1XS
LB1047-RCC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTN2Lk[5JI5O NVjRcndVW0GQR1XS
EM-2 NIDMVI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITSXXBKSzVyPUO4MlU{KG6P NH7VfllUSU6JRWK=
COLO-684 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrITWM2OD1|OT64JI5O MWfTRW5ITVJ?
Becker MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz4TWM2OD12MT6wOUBvVQ>? M1L3Z3NCVkeHUh?=
BL-41 MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPET3U{UUN3ME20N{43PiCwTR?= MXrTRW5ITVJ?
MDA-MB-134-VI MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPJTWM2OD12ND6wNkBvVQ>? M3nW[nNCVkeHUh?=
L-363 NYq5TVRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL5enUyUUN3ME20OE44OyCwTR?= MUDTRW5ITVJ?
ECC4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLjTWM2OD12ND63PEBvVQ>? MV3TRW5ITVJ?
A388 NE\ZS4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjLSHlKSzVyPUS0MlgzKG6P M4\STXNCVkeHUh?=
HEL NYfCeIY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXyTWM2OD12OT63PUBvVQ>? M{C2TnNCVkeHUh?=
RKO M332V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInuVIpKSzVyPUWwMlI6KG6P NFfBeJlUSU6JRWK=
KINGS-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETs[YVKSzVyPUWxMlU2KG6P Mmq0V2FPT0WU
EB-3 NV;ESZFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLVfWdkUUN3ME21Nk43PyCwTR?= MorNV2FPT0WU
ARH-77 M{[3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y3WWlEPTB;NUKuPEBvVQ>? NUnwcYQ{W0GQR1XS
GCIY NWjvSYplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nvcWlEPTB;NUOuOFYhdk1? MoLPV2FPT0WU
NCI-H1304 MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPHUW9KSzVyPUW3MlIzKG6P NHK1eY1USU6JRWK=
KARPAS-299 M1THZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\IVIpKSzVyPU[xMlgzKG6P NHHqb|RUSU6JRWK=
IA-LM NVTzfVlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGmye2dKSzVyPU[4MlE{KG6P M17jNXNCVkeHUh?=
GI-1 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTdyLkO5JI5O NUjxVWdmW0GQR1XS
TE-11 NX33UJp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXG2dVJvUUN3ME23O{4yPyCwTR?= NHrNXZJUSU6JRWK=
LS-411N NV7lfYF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnqbnpKSzVyPUe3MlU4KG6P NFT4cVNUSU6JRWK=
no-11 NECyO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\xZ2lEPTB;OEOuNlQhdk1? MmHsV2FPT0WU
MV-4-11 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfhfoFzUUN3ME24N{44OyCwTR?= NVrQZWgyW0GQR1XS
BV-173 Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTh|Lkm3JI5O MVHTRW5ITVJ?
CMK NWjXR2wyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTh2LkG2JI5O MU\TRW5ITVJ?
LC4-1 Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;2fGlEPTB;OE[uO|Ihdk1? NFzO[HZUSU6JRWK=
COR-L279 NWrrZVFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{GwT2lEPTB;OEeuNlUhdk1? M1\ZbnNCVkeHUh?=
NCI-H209 NWeyWZRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DJT2lEPTB;OEeuOFEhdk1? MmTmV2FPT0WU
Raji NWHzfnVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HZ[GlEPTB;OEmuO|Ihdk1? MV;TRW5ITVJ?
LB996-RCC NV3vVHhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTl|LkSzJI5O NUH6e4pUW0GQR1XS
NCI-H526 MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTQeGlMUUN3ME25N{42QSCwTR?= NXLYbXNpW0GQR1XS
KGN MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHmTWM2OD17Nj6yPUBvVQ>? MlrrV2FPT0WU
MOLT-4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\UR2lEPTB;OU[uO|khdk1? NVfz[I1{W0GQR1XS
PF-382 NGPkenJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv1XmxHUUN3ME25Ok44QSCwTR?= NUWzVZdrW0GQR1XS
BC-3 MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzSTWM2OD17OT6xPEBvVQ>? NEHLUmJUSU6JRWK=
KARPAS-422 MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTsTWM2OD1zMEKuNFkhdk1? M13VenNCVkeHUh?=
SBC-1 M4nQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLiPHExUUN3ME2xNFcvPzVibl2= NYn1TYNsW0GQR1XS
LC-1F MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfZS5lKSzVyPUGwPE4xPSCwTR?= NVPJNFJlW0GQR1XS
GB-1 NHL3RnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXPXohKSzVyPUGwPU4xOiCwTR?= Mn;CV2FPT0WU
SNB75 M{Hqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfCVYRKSzVyPUGxPU43QSCwTR?= NUfQdHZ2W0GQR1XS
BB65-RCC M4KzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInVTXZKSzVyPUGxPU46OyCwTR?= NUS3bZhEW0GQR1XS
NCI-N87 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnzOGk5UUN3ME2xNlEvQThibl2= MW\TRW5ITVJ?
IST-MEL1 NGDGWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHsTWM2OD1zMkKuN|ghdk1? MWTTRW5ITVJ?
HOP-62 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjk[GlKSzVyPUGyOk45QSCwTR?= M1TpVXNCVkeHUh?=
ACN M4\XXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorBTWM2OD1zNE[uO|Uhdk1? MXXTRW5ITVJ?
DMS-114 M2TmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfvVWxtUUN3ME2xOVAvPjdibl2= NF7mWWhUSU6JRWK=
MLMA MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF3OT64PEBvVQ>? M4\vfnNCVkeHUh?=
HT-144 NUPic4pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO5TWM2OD1zNkWuOFMhdk1? M2DQRXNCVkeHUh?=
C2BBe1 MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK1bIFKSzVyPUG2O{44PiCwTR?= MWjTRW5ITVJ?
L-428 MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF5Nz63JI5O NXWxZ4xuW0GQR1XS
DU-4475 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj4Xm5KSzVyPUG4O{43QCCwTR?= M{npUnNCVkeHUh?=
CP67-MEL M3jJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF7OT6zPEBvVQ>? NYD1WVVQW0GQR1XS
MEG-01 NIT2V2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoH4TWM2OD1{MEGuPVYhdk1? M1\3cnNCVkeHUh?=
IST-SL2 MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJyOD62N{BvVQ>? M{\EN3NCVkeHUh?=
ES8 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfNTWM2OD1{MkWuPVQhdk1? NVuyWZpFW0GQR1XS
COLO-800 M3m3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJ|NT6yPEBvVQ>? M{PJS3NCVkeHUh?=
MFH-ino M1vEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJ|NT64OEBvVQ>? MXvTRW5ITVJ?
OVCAR-4 MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofaTWM2OD1{M{euNlQhdk1? NIP1WGhUSU6JRWK=
PSN1 M2Kwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ2Mj63NUBvVQ>? NYHQZpdNW0GQR1XS
EW-12 M4Lt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnUcXd2UUN3ME2yOFMvOSCwTR?= NHPjU|RUSU6JRWK=
HCC1599 NGTpfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PZ[WlEPTB;Mk[xMlQ4KG6P NGrwWJZUSU6JRWK=
SJSA-1 NFHJWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPUfmZXUUN3ME2yO|EvPDZibl2= M1HNT3NCVkeHUh?=
ST486 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJ7Nj6xOEBvVQ>? MYPTRW5ITVJ?
NOMO-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq1b|ZKSzVyPUOwNE4zOSCwTR?= NYjGSXhtW0GQR1XS
MN-60 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVSyT5pJUUN3ME2zNFUvOzJibl2= MomzV2FPT0WU
HCC1187 M4C1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PzUmlEPTB;M{C3MlI2KG6P MYDTRW5ITVJ?
SW982 Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTNzND63OUBvVQ>? MUDTRW5ITVJ?
LB647-SCLC NH3sdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\zSWlEPTB;M{K4MlcyKG6P M4fE[HNCVkeHUh?=
HC-1 NUfsdZMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlWzTWM2OD1|M{WuOUBvVQ>? NE\PZ|JUSU6JRWK=
EHEB NEX3eZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXFcWFHUUN3ME2zN|cvPTJibl2= NIfXUpVUSU6JRWK=
TUR M4DFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDmd4hKSzVyPUO2N{46PSCwTR?= M4PuV3NCVkeHUh?=
LU-139 MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEmyb5NKSzVyPUO3PE4xOiCwTR?= MVHTRW5ITVJ?
NB1 M{Lhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrmTWM2OD1|OESuOFUhdk1? NXnyPGxUW0GQR1XS
BB30-HNC NX3GN5FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;0eWlEPTB;M{i4MlMzKG6P M3iwcHNCVkeHUh?=
HAL-01 NHS3SGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTN6OT6yOkBvVQ>? MX;TRW5ITVJ?
K5 M2TvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTRzMT6zO{BvVQ>? NHTPfJRUSU6JRWK=
MZ2-MEL NEHwUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnFN3p6UUN3ME20NVMvPjRibl2= MWPTRW5ITVJ?
RXF393 Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTRzNj60OUBvVQ>? M2HhfXNCVkeHUh?=
NCI-H1648 NF;MOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTRzNz61N{BvVQ>? M4HGUXNCVkeHUh?=
TE-12 M37FSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7jTWM2OD12M{SuNlYhdk1? NELXXotUSU6JRWK=
EoL-1- M1Ptc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfvOZpKSzVyPUSzO{46QCCwTR?= M1PET3NCVkeHUh?=
JAR M4LPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TtSGlEPTB;NEO4MlYzKG6P NEP2T2FUSU6JRWK=
DSH1 MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1mwTmlEPTB;NEW4MlkyKG6P NGTNe4RUSU6JRWK=
NCI-H187 M2LrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTR4Mj64NUBvVQ>? MlrGV2FPT0WU
HCE-4 NU\qNIpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LOfWlEPTB;NEe3MlY3KG6P M4fSZ3NCVkeHUh?=
8-MG-BA M3nTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnhO5VEUUN3ME21PFEvPTJibl2= MlvDV2FPT0WU
KLE MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTV6NT6yJI5O M1LobnNCVkeHUh?=
KNS-42 M4XHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzu[3BKUUN3ME21PFYvQDFibl2= NYi2RXVEW0GQR1XS
MSTO-211H NVrXZ2cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C2OGlEPTB;NkC5Mlc1KG6P NWTQV2M6W0GQR1XS
GDM-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPoTWM2OD14MUSuNFkhdk1? MWLTRW5ITVJ?
TE-1 NGXGSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSxTWM2OD14NE[uNVIhdk1? M2DNTXNCVkeHUh?=
BT-474 NUnweGlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV64VIRMUUN3ME22OFcvODZibl2= MXnTRW5ITVJ?
KARPAS-45 M1LTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTZ2Nz62JI5O NHyxVmFUSU6JRWK=
MOLT-16 NEDGfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LVdGlEPTB;NkS3Mlk{KG6P M1HjNHNCVkeHUh?=
KURAMOCHI MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTZ3Nz61NUBvVQ>? MoDiV2FPT0WU
K-562 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nkTmlEPTB;Nk[5MlUyKG6P NUXkWHFoW0GQR1XS
EKVX NGLKNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nrc2lEPTB;NkeyMlcyKG6P NUfFNJlbW0GQR1XS
GAK MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn5UIZKSzVyPU[3OU4{KG6P MUjTRW5ITVJ?
NCI-SNU-5 MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LLSWlEPTB;NkmwMlAyKG6P NX;w[HBwW0GQR1XS
NCI-H2126 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;XVYxKSzVyPUeyOk45PyCwTR?= NHX3U5pUSU6JRWK=
CTV-1 NYPFc5hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTd2ND65JI5O MYrTRW5ITVJ?
SW962 NF[ze21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1u3c2lEPTB;N{S4MlQ1KG6P MX\TRW5ITVJ?
MONO-MAC-6 NFjGWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7HTWM2OD15NU[uPVMhdk1? MWrTRW5ITVJ?
NCI-H748 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGftbWpKSzVyPUe1PE46QSCwTR?= NFixRYtUSU6JRWK=
NCI-H524 M2fR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHETWM2OD15OECuO|Mhdk1? MYLTRW5ITVJ?
LS-123 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\ENmY3UUN3ME23PVUvPjlibl2= NUTzbWh6W0GQR1XS
NB7 NFzjUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LOcmlEPTB;OEG0MlE1KG6P NUL1eoF1W0GQR1XS
LS-1034 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXXUpBVUUN3ME24NlgvQThibl2= NHyzPVNUSU6JRWK=
TE-5 NFHYfGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj3TWM2OD16OEOuOVYhdk1? MnW0V2FPT0WU
A704 NGPnPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTh7OT6xOUBvVQ>? MWnTRW5ITVJ?
TK10 NYDkcHVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny2TWM2OD17MU[uNFMhdk1? NUjmeGkyW0GQR1XS
NCI-H345 NV3meZJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjRSFVFUUN3ME25OFMvOjJibl2= M3PEV3NCVkeHUh?=
CGTH-W-1 M{[2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u3OmlEPTB;OUS4MlE{KG6P MmrqV2FPT0WU
NCI-H510A NWWwUJh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\xOWlEPTB;OUi1MlEzKG6P M3S4c3NCVkeHUh?=
NCI-H1963 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwMEOyPVIh|ryP MYLTRW5ITVJ?
SCC-3 MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TmOGlEPTB;MT6wN|QyPCEQvF2= NHz4[5BUSU6JRWK=
EW-11 NIGwR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvkTWM2OD1zLkC4O|Q{KM7:TR?= M1LZcHNCVkeHUh?=
CPC-N M4rLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln2TWM2OD1zLkC4PEDPxE1? NX;zS4dkW0GQR1XS
NCI-H1417 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF73cYFKSzVyPUGuNVIzPiEQvF2= NWj4WW45W0GQR1XS
DG-75 M2jJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PPfmlEPTB;MT6xOlI5PSEQvF2= M1;CPHNCVkeHUh?=
HD-MY-Z MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jyemlEPTB;MT6xOlQyPiEQvF2= M{mwPXNCVkeHUh?=
ATN-1 NUHp[FJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\H[IdKSzVyPUGuNlYzODlizszN MWHTRW5ITVJ?
KM-H2 NV3MW4oyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7MU285UUN3ME2xMlI3PDB6IN88US=> Mn7KV2FPT0WU
NCI-H2081 Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HMOWlEPTB;MT6yOlY{PyEQvF2= NFjYXY1USU6JRWK=
HL-60 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITJSI9KSzVyPUGuNlY6PTlizszN NGC5fIVUSU6JRWK=
DB M1vhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzsS5ZKSzVyPUGuNlczPDJizszN M2HwXXNCVkeHUh?=
NCI-H1522 Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLoTWM2OD1zLkK4PFg4KM7:TR?= Ml2xV2FPT0WU
AM-38 M2j3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPxdod6UUN3ME2xMlMxPzJizszN M13veXNCVkeHUh?=
NCI-H446 NYPKcGI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjQXZNKSzVyPUGuN|IyOjFizszN NXH3ZY4{W0GQR1XS
SU-DHL-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknSTWM2OD1zLkOyPFAyKM7:TR?= MXrTRW5ITVJ?
NH-12 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTFwM{[zO|Qh|ryP MYfTRW5ITVJ?
DMS-79 M3jNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37qbmlEPTB;MT6zOlg3PiEQvF2= MmTOV2FPT0WU
NCI-H716 NHPxVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf4OoxKSzVyPUGuN|g6QDZizszN MlXOV2FPT0WU
ML-2 NUfBS|dET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknnTWM2OD1zLkSxOVI6KM7:TR?= NWLLUoZXW0GQR1XS
NB10 NG\oZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[2TWM2OD1zLkS2OlMzKM7:TR?= NIPRTlBUSU6JRWK=
ONS-76 M2nJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXlcIJzUUN3ME2xMlU{PTZ7IN88US=> MmjkV2FPT0WU
LOUCY MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PLbGlEPTB;MT61OFY2PyEQvF2= M2TXT3NCVkeHUh?=
SCLC-21H NHXCXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPTZmFDUUN3ME2xMlU5PTh{IN88US=> MlvHV2FPT0WU
TGW NFXhW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjjTWlKSzVyPUGuOlM6PzVizszN Mn3QV2FPT0WU
LXF-289 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwN{OyOlgh|ryP NXfQV4FxW0GQR1XS
BB49-HNC NYS5O3ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\OTWM2OD1zLkezOVg3KM7:TR?= MkOyV2FPT0WU
NCI-H747 M{Dafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjFXXZKSzVyPUGuO|U{PDZizszN Mlu1V2FPT0WU
LU-165 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jIXGlEPTB;MT64OFk5PiEQvF2= M4DNOHNCVkeHUh?=
OMC-1 NYPiRY5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n4c2lEPTB;MT65OVA3PiEQvF2= MWnTRW5ITVJ?
RCC10RGB MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTK[GZKSzVyPUGuPVU5OTdizszN MWjTRW5ITVJ?
SW684 NIHLTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK4OpB2UUN3ME2xMlk3ODl7IN88US=> MV;TRW5ITVJ?
TE-8 M123Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXVb4ZwUUN3ME2yMlA2PTV7IN88US=> MV;TRW5ITVJ?
SK-N-DZ M3;YUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ftXGlEPTB;Mj6xN|I4PCEQvF2= NFXWU5FUSU6JRWK=
EVSA-T NVLIdm9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrhZ4JKSzVyPUKuNVc{OTVizszN MUHTRW5ITVJ?
KASUMI-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XxUGlEPTB;Mj6xPFgyPSEQvF2= NUjTWFJOW0GQR1XS
NKM-1 MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDRTWM2OD1{LkK1OFczKM7:TR?= M4nNPHNCVkeHUh?=
CAL-148 MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPFNY1KSzVyPUKuN|M3OTRizszN M1PjWHNCVkeHUh?=
NCI-H64 NUL0N4loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;zWWlEPTB;Mj6zOFI{OiEQvF2= MXjTRW5ITVJ?
KNS-81-FD M3fHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXKTWM2OD1{LkO2OlIh|ryP NXLvOIcyW0GQR1XS
KM12 M3jOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\lTWM2OD1{LkSwPFM6KM7:TR?= MoHRV2FPT0WU
SW954 MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7hTWM2OD1{LkS3O|c6KM7:TR?= NXLTfVROW0GQR1XS
NCI-H1395 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LGUmlEPTB;Mj61NlY1PSEQvF2= NH;mfmdUSU6JRWK=
DJM-1 NHH2SlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vkU2lEPTB;Mj62NFY{KM7:TR?= M2DGeXNCVkeHUh?=
COLO-668 Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\TOpNKSzVyPUKuPFI3QTVizszN MnPtV2FPT0WU
NCI-H1436 NELJNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;YTXhOUUN3ME2yMlg2PjF3IN88US=> NUnYO5lUW0GQR1XS
LB2241-RCC MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3Ndo9lUUN3ME2yMlg3QDN7IN88US=> NWfFSoIyW0GQR1XS
GT3TKB NHvnSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJwOEmwOVUh|ryP NGLPTllUSU6JRWK=
COLO-824 M2nsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHofVlzUUN3ME2yMlg6PzZ6IN88US=> NFvuUpRUSU6JRWK=
ES1 M133Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzJN4xKSzVyPUKuPFk5PzlizszN Ml;OV2FPT0WU
LB771-HNC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G4VWlEPTB;Mj65NFk1PiEQvF2= M{\kOXNCVkeHUh?=
GI-ME-N Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTBeWs6UUN3ME2zMlAxQTB2IN88US=> MnXoV2FPT0WU
NALM-6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO5NlNvUUN3ME2zMlAxQTN|IN88US=> M{n0RXNCVkeHUh?=
LU-134-A M3mxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XDNmlEPTB;Mz6wOVQzPSEQvF2= MYXTRW5ITVJ?
DMS-153 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTNwMEW4NlQh|ryP NITLS5FUSU6JRWK=
MZ1-PC M3vCN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTNwMEmwO|gh|ryP MWLTRW5ITVJ?
NCI-H1155 NWe2botNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnuzTWM2OD1|LkGxOlEh|ryP NXXucXhmW0GQR1XS
CAS-1 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z5[mlEPTB;Mz6xN|cxPyEQvF2= MYrTRW5ITVJ?
D-502MG M1H0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlKwTWM2OD1|LkG0N|kh|ryP MVTTRW5ITVJ?
NCI-H2141 M3zycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme3TWM2OD1|LkG3OFUzKM7:TR?= M2PSOXNCVkeHUh?=
NB6 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofOTWM2OD1|LkG4NlU6KM7:TR?= NWj5OYpqW0GQR1XS
NCCIT M13ONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTzfpRCUUN3ME2zMlIyQDB7IN88US=> Mo\CV2FPT0WU
NB69 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHEXmJKSzVyPUOuN|E5QTFizszN M37mRXNCVkeHUh?=
JVM-2 NFTveI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjkTXdKSzVyPUOuN|Y1OzNizszN NFK5[JdUSU6JRWK=
K052 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDyTWM2OD1|LkO3PVY5KM7:TR?= M3fP[3NCVkeHUh?=
HCC2157 NIL0empIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXQeYJKSzVyPUOuOVMzOjhizszN MlG3V2FPT0WU
KMOE-2 MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\QZ4tKSzVyPUOuOVQzPDJizszN M{mwfXNCVkeHUh?=
SF268 M4j5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTNwN{G1OVQh|ryP NFH3d4JUSU6JRWK=
CHP-126 NGnPVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzkTWM2OD1|Lke2OFU5KM7:TR?= M2DmcnNCVkeHUh?=
CP66-MEL M2TifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XYZmlEPTB;Mz63PVA6PCEQvF2= MWnTRW5ITVJ?
NCI-H69 NYrESWJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTRwMEG5N|Yh|ryP NY[zdmNYW0GQR1XS
A253 NULoNWRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTqVpVrUUN3ME20MlAzOTBzIN88US=> MUXTRW5ITVJ?
NB14 M{fYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n0TmlEPTB;ND6xNFQ4QSEQvF2= M4HySXNCVkeHUh?=
NCI-H1694 M{PTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnsTWM2OD12LkGzNVEzKM7:TR?= M2XyN3NCVkeHUh?=
NCI-H2196 NYDNXlNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnFTJRKSzVyPUSuNVcyPjlizszN MUTTRW5ITVJ?
TE-9 NUPWVGZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjXem1SUUN3ME20MlE4PTh{IN88US=> MYfTRW5ITVJ?
D-283MED M2qz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q1TWlEPTB;ND6xPFg1KM7:TR?= MXjTRW5ITVJ?
OCI-AML2 Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnLR4tKSzVyPUSuNVk1QDlizszN M1HS[XNCVkeHUh?=
D-263MG M{exbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTRwMkK5OlEh|ryP MmT1V2FPT0WU
MPP-89 NYPySHFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H0PWlEPTB;ND6yO|MxPCEQvF2= NVvkbFdDW0GQR1XS
LAMA-84 M4rpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTRwM{C0NlEh|ryP M{fZRXNCVkeHUh?=
LB373-MEL-D NXXpc|d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTRwM{[3PFkh|ryP NYDvfG85W0GQR1XS
UACC-257 M3XnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfuVGlKSzVyPUSuN|k2OzRizszN NV3XZWgxW0GQR1XS
MC-CAR MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jwcWlEPTB;ND60N|k6KM7:TR?= NVzyTWlIW0GQR1XS
COLO-320-HSR MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHlXZpQUUN3ME20MlQ1PDJ5IN88US=> MX;TRW5ITVJ?
P30-OHK NYL1doF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;0b2lEPTB;ND62OlU5OSEQvF2= NF\SNmZUSU6JRWK=
UACC-812 Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[5UXF2UUN3ME20MlY6OTZzIN88US=> MoX2V2FPT0WU
CTB-1 NHP3NoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rQdmlEPTB;ND63NVU2PSEQvF2= MUjTRW5ITVJ?
ALL-PO MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHWTWM2OD12Lki0NFc4KM7:TR?= MoPHV2FPT0WU
SK-MEL-2 NIXzT25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfrTWM2OD12Lki2PVU2KM7:TR?= NYHrZWQ4W0GQR1XS
TC-YIK MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf0TWM2OD12Lkm3PVQzKM7:TR?= NEn0VWdUSU6JRWK=
NCI-H1882 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fKW2lEPTB;NT6wNlAxOSEQvF2= NFfxR4dUSU6JRWK=
MHH-CALL-2 M{HVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnBcGlKSzVyPUWuNFUxPDJizszN NUm0W45xW0GQR1XS
U-87-MG NXPCUGV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DMTmlEPTB;NT6wPVQ3PiEQvF2= NHLKclBUSU6JRWK=
NCI-H1092 M4TRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvibXA2UUN3ME21MlI3PTV3IN88US=> NXvWUYhqW0GQR1XS
TE-441-T NX;X[YdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrwRY86UUN3ME21MlI4QDJizszN M1jkO3NCVkeHUh?=
SK-MEL-1 MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTVwMkmwOFQh|ryP M4nHUHNCVkeHUh?=
EW-22 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTVwMkm0OlYh|ryP NWLiXZB7W0GQR1XS
MZ7-mel M13sZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHjUnZKSzVyPUWuOFA3QTFizszN NXzkVmZ7W0GQR1XS
LP-1 M4\E[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\lN2lEPTB;NT60NVI6OSEQvF2= MX7TRW5ITVJ?
NCI-SNU-16 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n2bWlEPTB;NT62OFA4PCEQvF2= MoPvV2FPT0WU
LU-65 MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTVwN{[zO|Mh|ryP MkjTV2FPT0WU
CW-2 NGnWTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTVwOEW5OVkh|ryP NUe0ZnZSW0GQR1XS
WSU-NHL NFPBUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKwelFKSzVyPUWuPVUyPzRizszN M17LbXNCVkeHUh?=
IST-MES1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DQSmlEPTB;NT65OVQ1OyEQvF2= NFPTNllUSU6JRWK=
U-266 NHnYS5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTVwOUiyNFIh|ryP MmDUV2FPT0WU
TALL-1 MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[2TWM2OD14LkG0Olg5KM7:TR?= MVXTRW5ITVJ?
Calu-6 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTZwMUWzNVYh|ryP NEPkXXBUSU6JRWK=
MMAC-SF NXrJWVZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTZwMUi1OVYh|ryP MlfNV2FPT0WU
NCI-H82 Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljqTWM2OD14LkKwOFg6KM7:TR?= MWTTRW5ITVJ?
RS4-11 M4\XWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrMOJlKSzVyPU[uNlU5QTdizszN M2Lte3NCVkeHUh?=
SNU-C2B MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fEeGlEPTB;Nj60NFk3QSEQvF2= NYDBNZVRW0GQR1XS
BOKU M3fTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTZwNEe1PVch|ryP NH\Oc4pUSU6JRWK=
C8166 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTZwNUW5NVIh|ryP M{LEe3NCVkeHUh?=
D-247MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\kdGlEPTB;Nz6wOFM1PyEQvF2= M{PXZnNCVkeHUh?=
EW-18 M2HL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjzTWM2OD15LkC3NlkzKM7:TR?= NYPHb25NW0GQR1XS
KG-1 M{WyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLrblF[UUN3ME23MlYzPzN6IN88US=> NHj1fllUSU6JRWK=
REH M3X1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPSWmNKSzVyPUeuOlgyODlizszN MmrCV2FPT0WU
U-698-M NITkVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTnV2t[UUN3ME23Mlg1OzF3IN88US=> NWD6TZRIW0GQR1XS
KP-N-RT-BM-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmyTWM2OD15LkmzNFI6KM7:TR?= M3jYOXNCVkeHUh?=
MS-1 M{PWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPue4J{UUN3ME23Mlk3ODRzIN88US=> NECyXVZUSU6JRWK=
SNU-C1 M3LNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIeyfHZKSzVyPUeuPVgyQTJizszN NXT1RodxW0GQR1XS
SK-MM-2 NIXHUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jJPGlEPTB;OD6yOlA3PSEQvF2= MlzSV2FPT0WU
LAN-6 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRThwM{CwNFEh|ryP MmraV2FPT0WU
NEC8 NFHuU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrUTWM2OD16LkOwOlkyKM7:TR?= NHj6XVBUSU6JRWK=
NCI-H1770 NXzDemlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRThwM{iwNFIh|ryP NVv6UmsyW0GQR1XS
D-336MG NWSyc2NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPW[mRUUUN3ME24MlQxOTF4IN88US=> NU\pcWJNW0GQR1XS
COLO-829 NWTM[pRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO3SnZPUUN3ME24MlQ5QDd7IN88US=> NVrWNpFjW0GQR1XS
LS-513 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRThwNUm1PVkh|ryP NE\BRmFUSU6JRWK=
YT NFThfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPsTWM2OD16Lk[yOFI4KM7:TR?= M4DJTnNCVkeHUh?=
EW-24 NFHITlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DoS2lEPTB;OD63OlU1KM7:TR?= NX[4XZZQW0GQR1XS
IST-SL1 MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRThwOE[1OFMh|ryP NEmxTZhUSU6JRWK=
CA46 Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXRTWM2OD16Lkm1NFk5KM7:TR?= NXvidlh7W0GQR1XS
NCI-H1838 NXjqbHhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoewTWM2OD16Lkm4OlAzKM7:TR?= M2TKe3NCVkeHUh?=
NCI-H719 NHTa[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XKU2lEPTB;OT6yOVI4QSEQvF2= NGTwNplUSU6JRWK=
HCE-T MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTlwM{C4OVEh|ryP NXmycoR2W0GQR1XS
A498 NIrtSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zhU2lEPTB;OT6zOlEzPCEQvF2= NVvIVJg4W0GQR1XS
LB831-BLC MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPBZllnUUN3ME25Mlc3PTJzIN88US=> NEfzU2tUSU6JRWK=
SKM-1 NIO5XGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\HRW9DUUN3ME25Mlg2QTZ|IN88US=> NH\rWGVUSU6JRWK=
THP-1 M1\QPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFmxO|RKSzVyPUmuPVY6OThizszN MlqwV2FPT0WU
SHP-77 NHPFVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPpXXZKSzVyPUGwMlQxPyEQvF2= Mn[1V2FPT0WU
EW-3 M3TtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDSWm1KSzVyPUGwMlYzQDlizszN MmrpV2FPT0WU
KY821 NETr[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nJRmlEPTB;MUCuO|Y{KM7:TR?= NFvDU|RUSU6JRWK=
NCI-SNU-1 Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD3TWM2OD1zMT6wNlE4KM7:TR?= MUjTRW5ITVJ?
HCC2218 NH\BcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[zO4tKSzVyPUGxMlM6QDZizszN M4eyTXNCVkeHUh?=
IM-9 NGX4PWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPXXo5SUUN3ME2xNU42OTB4IN88US=> NFfjZmZUSU6JRWK=
NCI-H889 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFzLkWzNVMh|ryP M4fTVnNCVkeHUh?=
HDLM-2 MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTF{LkSxOVkh|ryP NYXHcndRW0GQR1XS
LB2518-MEL MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF{Lk[4NVUh|ryP NVX3VYVTW0GQR1XS
NCI-H23 M4DtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof3TWM2OD1zMz6yOFI2KM7:TR?= MoXBV2FPT0WU
NB17 NFjsbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnrTWM2OD1zMz60OVc6KM7:TR?= MXLTRW5ITVJ?
NCI-H322M NVrMcGZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvuZ4dKSzVyPUG0MlQxPjhizszN NH3oTFlUSU6JRWK=
SUP-T1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Lzb2lEPTB;MUSuOFE{KM7:TR?= MUXTRW5ITVJ?
ES3 NILDZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz1dlRSUUN3ME2xOU4xPzB|IN88US=> NXfHU5pKW0GQR1XS
ES5 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH6OmRQUUN3ME2xOU4xPzh5IN88US=> M2DmNHNCVkeHUh?=
NCI-H1650 M160Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT2TWM2OD1zNT60PVc6KM7:TR?= NVvSVlZkW0GQR1XS
NCI-H226 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\STWM2OD1zNT64O|Y5KM7:TR?= NE\ENXNUSU6JRWK=
COR-L88 NI\TVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3KXJdKSzVyPUG2MlMyPCEQvF2= M{TueHNCVkeHUh?=
SCC-15 M4fZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDienBKSzVyPUG2MlM5PjlizszN MV3TRW5ITVJ?
GOTO MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfuTWM2OD1zNj60O|k{KM7:TR?= NFG0cZFUSU6JRWK=
SIMA NUXJTpdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4iySGlEPTB;MU[uOFgxOiEQvF2= NHPDOYVUSU6JRWK=
NCI-H1299 NUTjfYd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PSbGlEPTB;MUeuNVU6OSEQvF2= NV;FRYZVW0GQR1XS
NCI-H1581 NYLSbY5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF5LkSyNVkh|ryP NV\UW5d5W0GQR1XS
MHH-NB-11 MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPtVJlzUUN3ME2xO{46Pjh|IN88US=> MmThV2FPT0WU
MFM-223 NX3HXY5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K1TGlEPTB;MUiuNFU{QCEQvF2= MWDTRW5ITVJ?
ES7 M4rE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF6LkW0N|Eh|ryP NUHQdGd3W0GQR1XS
JVM-3 MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnnTWM2OD1zOD63NVch|ryP MUnTRW5ITVJ?
RL Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJyLkO4PEDPxE1? M{fC[nNCVkeHUh?=
EC-GI-10 NVW2SGZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mli0TWM2OD1{MT6yNFQyKM7:TR?= NIXSZXNUSU6JRWK=
LNCaP-Clone-FGC NILwWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrKc5ZqUUN3ME2yNU43PzZ6IN88US=> NUHzcVdCW0GQR1XS
IMR-5 M3PvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJzLki0PVQh|ryP NVTrWmliW0GQR1XS
KP-N-YS M4DNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuzd2ZKSzVyPUKxMlg4PSEQvF2= MlHkV2FPT0WU
Mo-T NVi1U5BsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJ{LkKxPFUh|ryP MV\TRW5ITVJ?
NCI-H128 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJ|LkW4OVMh|ryP NVzN[HZXW0GQR1XS
RH-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rM[mlEPTB;MkOuO|g3PiEQvF2= M4fqe3NCVkeHUh?=
NCI-H2171 NGCxeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXjTWM2OD1{ND6yOFg2KM7:TR?= NVfCTVNmW0GQR1XS
RPMI-8866 NILRdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4mzS2lEPTB;Mk[uO|QzKM7:TR?= NGr6NYpUSU6JRWK=
SK-N-FI NYjXPIV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJ5LkO4NVEh|ryP NWG4c5BEW0GQR1XS
LOXIMVI Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHXc|VKSzVyPUK3MlgxPTFizszN M2DmZXNCVkeHUh?=
P31-FUJ MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDwTWM2OD1|MT61N|c1KM7:TR?= MVTTRW5ITVJ?
KMS-12-PE M4jxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vtWGlEPTB;NEmuOVMxOiEQvF2= NUe3S3pvW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID